xamoterol has been researched along with atropine in 5 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 26,711 | 1,259 | 1,697 |
| Protein | Taxonomy | xamoterol (IC50) | atropine (IC50) |
|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
5 other study(ies) available for xamoterol and atropine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |